Publications
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine, Second Faculty of Medicine
- Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma2018 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine, Second Faculty of Medicine
- Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance2018 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine, Second Faculty of Medicine
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
Loading network view...